Factors that affect serum levels of ferritin in Australian adults and implications for follow-up
MetadataShow full item record
Background & Aims: Serum levels of ferritin are commonly measured to assess iron stores but are affected by factors such as obesity and chronic disease. Published reference ranges have not changed in decades, and the number of patients whose levels exceed the upper limits has been increasing. As a result, more patients are evaluated for iron overload. Methods: We compared serum levels of ferritin in 1188 Australian adults who participated in the 2005 Busselton Population Survey with levels from the 1995 survey. Parametric regression was used to assess the effects of body weight and biochemical parameters on serum level of ferritin to derive contemporary population-appropriate reference ranges.Results: In 2005, age-adjusted levels of ferritin were 21% higher in men (P < .0001) and 10% higher in women (P = .01) than in 1995; 31% of men exceeded levels of 300 μg/L, compared with 23% in 1995. Body mass index (BMI) ≥25 kg/m2 was associated with higher levels of ferritin in men ≥35 years old and in postmenopausal women (P ≤ .002). Serum level of γ-glutamyltransferase (GGT) correlated with serum level of ferritin (P < .0001). In men, the estimated 95th percentiles ranged from 353 to 495 μg/L (<35 years), from 350 to 511 μg/L (≥35 years, BMI <25 kg/m2), and from 413 to 696 μg/L (≥35 years, BMI ≥25 kg/m2) when GGT levels were 10–75 IU/L. In women, the 95th percentiles ranged from 106 to 235 μg/L (premenopausal), from 222 to 323 μg/L (postmenopausal, BMI <25 kg/m2), and from 249 to 422 μg/L (postmenopausal, BMI ≥25 kg/m2) when GGT levels were 8–45 IU/L. Conclusion: Serum levels of ferritin increased significantly between 1995 and 2005. Reference ranges that accommodate demographic and biomedical variations will assist clinicians in identifying individuals who require further evaluation for iron overload.
NOTICE: this is the author’s version of a work that was accepted for publication in Clinical Gastroenterology and Hepatology resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Clinical Gastroenterology and Hepatology, Vol. 12, No. 1 (2014). DOI: 10.1016/j.cgh.2013.07.019
Showing items related by title, author, creator and subject.
Reduction of body iron in HFE-related haemochromatosis and moderate iron overload (Mi-Iron): a multicentre, participant-blinded, randomised controlled trialOng, S.; Gurrin, L.; Dolling, L.; Dixon, J.; Nicoll, A.; Wolthuizen, M.; Wood, E.; Anderson, G.; Ramm, G.; Allen, K.; Olynyk, John; Crawford, D.; Ramm, L.; Gow, P.; Durrant, S.; Powell, L.; Delatycki, M. (2017)© 2017 Elsevier Ltd Background The iron overload disorder hereditary haemochromatosis is most commonly caused by HFE p.Cys282Tyr homozygosity. In the absence of results from any randomised trials, current evidence is ...
Higher ferritin levels, but not serum iron or transferrin saturation, are associated with Type 2 diabetes mellitus in adult men and women free of genetic haemochromatosisYeap, B.; Divitini, M.; Gunton, J.; Olynyk, John; Beilby, J.; McQuillan, B.; Hung, J.; Knuiman, M. (2015)Context - Iron overload predisposes to diabetes and higher ferritin levels have been associated with diabetes. However, it is unclear whether ferritin reflects differences in iron-related parameters between diabetic and ...
Characterization of hepatic and cardiac iron deposition during standard treatment of anaemia in haemodialysisHolman, R.; Olynyk, John; Kulkarni, H.; Ferrari, P. (2017)Background: Parenteral iron is integral in the treatment of anaemia of chronic kidney disease patients on haemodialysis (HD). However, increased liver iron concentration (LIC) can result from such treatment, and this ...